Document Detail


Liraglutide in type 2 diabetes: from pharmacological development to clinical practice.
MedLine Citation:
PMID:  19848045     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The novel drug class of GLP-1 analogues is extremely promising, since existing evidence suggests they can address many of the unmet needs of diabetes treatment, i.e., long-term efficacy, low risk of hypoglycemia, cardiovascular protection, weight loss, long-term safety and tolerability. Besides the already available exenatide, liraglutide is expected to arrive soon on the market. It is a human GLP-1 analogue with high homology (97%) to native hormone. A comprehensive phase III evaluation consisting of six randomized clinical trials--the "Liraglutide Effect and Action Diabetes (LEAD) program"--was recently completed, involving 6500 people seen in 600 sites in 41 countries worldwide. Aim of the LEAD program was to evaluate efficacy and safety of liraglutide as monotherapy and in combination with commonly used antidiabetic drugs. In all studies, once-daily liraglutide was well tolerated, significantly improved metabolic control, and reduced body weight, with low rates of hypoglycemia. Transient nausea was the most common side effects. Additional beneficial effects ofliraglutide on beta-cell function, systolic blood pressure, and cardiovascular risk were also documented. If these encouraging results will be confirmed by long-term studies, liraglutide will acquire a prominent role among the main therapeutic options not only as add-on treatments in case of secondary failure, but also as an early strategy to reduce the burden of diabetes and its complications.
Authors:
Maria Chiara Rossi; Antonio Nicolucci
Related Documents :
2122145 - Gastric inhibitory polypeptide mechanisms of augmenting insulin secretion.
15561915 - Stimulation of insulin secretion by intravenous bolus injection and continuous infusion...
9436865 - The ethanol augmentation of glucose-induced insulin secretion is abolished by calcium a...
2497435 - Functional enteroinsular axis in full-term newborn infants.
20463885 - Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced in...
10091405 - Co-inherited gilbert's syndrome: a factor determining hyperbilirubinemia in homozygous ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Acta bio-medica : Atenei Parmensis     Volume:  80     ISSN:  0392-4203     ISO Abbreviation:  Acta Biomed     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-10-23     Completed Date:  2009-12-11     Revised Date:  2013-05-13    
Medline Journal Info:
Nlm Unique ID:  101295064     Medline TA:  Acta Biomed     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  93-101     Citation Subset:  IM    
Affiliation:
Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Chieti, Italy. mrossi@negrisud.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Diabetes Mellitus, Type 2 / drug therapy*
Drug Evaluation, Preclinical
Glucagon-Like Peptide 1 / analogs & derivatives*,  therapeutic use
Humans
Treatment Outcome
Chemical
Reg. No./Substance:
839I73S42A/liraglutide; 89750-14-1/Glucagon-Like Peptide 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Medicine on mission: The international health reform of Seventh-Day Adventists and their health care...
Next Document:  Airway clearance therapy in cystic fibrosis patients.